Publications
2024
Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis.
Bermejo-Rodriguez, C., Araos Henríquez, J., Caligiuri, G., Pinto Teles, S., Park, Y., Evans, A., . . . Perez-Mancera, P. A. (2024). Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis.. Cancer research. doi:10.1158/0008-5472.can-23-3419
Chemotherapy Assessment in Advanced Multicellular 3D Models of Pancreatic Cancer: Unravelling the Importance of Spatiotemporal Mimicry of the Tumor Microenvironment
Gupta, P., Bermejo-Rodriguez, C., Kocher, H., Pérez-Mancera, P. A., & Velliou, E. G. (2024). Chemotherapy Assessment in Advanced Multicellular 3D Models of Pancreatic Cancer: Unravelling the Importance of Spatiotemporal Mimicry of the Tumor Microenvironment. Advanced Biology. doi:10.1002/adbi.202300580
2023
The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis
Barrera, L. N., Ridley, P. M., Bermejo-Rodriguez, C., Costello, E., & Perez-Mancera, P. A. (2023). The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis. JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, 79(1), 193-204. doi:10.1007/s13105-022-00899-0
2022
Abstract C084: Oncogenic KRAS signaling drives the activation of tissue-resident fibroblasts and is required to maintain CAF heterogeneity in pancreatic cancer
Caligiuri, G., Thalappillil, J. S., Shakiba, M., Nadella, S., Hinds, J., Courtois, E., . . . Tuveson, D. A. (2022). Abstract C084: Oncogenic KRAS signaling drives the activation of tissue-resident fibroblasts and is required to maintain CAF heterogeneity in pancreatic cancer. Cancer Research, 82(22_Supplement), C084. doi:10.1158/1538-7445.panca22-c084
Abstract 3647: Oncogenic Kras drives cancer-associated fibroblast heterogeneity and substate changes in pancreatic cancer
Thalappillil, J. S., Caligiuri, G., Nadella, S., Alagesan, B., Yordanov, G. N., Shakiba, M., . . . Tuveson, D. A. (2022). Abstract 3647: Oncogenic Kras drives cancer-associated fibroblast heterogeneity and substate changes in pancreatic cancer. Cancer Research, 82(12_Supplement), 3647. doi:10.1158/1538-7445.am2022-3647
Oncogenic KRAS signaling drives the activation of tissue-resident fibroblasts and is required to maintain CAF heterogeneity in pancreatic cancer.
Caligiuri, G., Thalappillil, J. S., Shakiba, M., Nadella, S., Hinds, J., Courtois, E., . . . Tuveson, D. A. (2022). Oncogenic KRAS signaling drives the activation of tissue-resident fibroblasts and is required to maintain CAF heterogeneity in pancreatic cancer.. In CANCER RESEARCH Vol. 82 (pp. 168). Retrieved from https://www.webofscience.com/
Oncogenic Kras drives cancer-associated fibroblast heterogeneity and substate changes in pancreatic cancer
Thalappillil, J. S., Caligiuri, G., Nadella, S., Alagesan, B., Yordanov, G. N., Shakiba, M., . . . Tuveson, D. A. (2022). Oncogenic Kras drives cancer-associated fibroblast heterogeneity and substate changes in pancreatic cancer. In CANCER RESEARCH Vol. 82. Retrieved from https://www.webofscience.com/
2020
ON THE DEVELOPMENT OF A BIOINSPIRED, BIOMIMETIC PANCREATIC CANCER MODEL: ENGINEERING A HYBRID SCAFFOLD ASSISTED IN VITRO MULTICELLULAR MODEL OF PANCREATIC CANCER
Gupta, P., Pérez-Mancera, P. A., Kocher, H., Nisbet, A., Schettino, G., & Velliou, E. G. (2020). ON THE DEVELOPMENT OF A BIOINSPIRED, BIOMIMETIC PANCREATIC CANCER MODEL: ENGINEERING A HYBRID SCAFFOLD ASSISTED IN VITRO MULTICELLULAR MODEL OF PANCREATIC CANCER. Pancreatology, 20(8), e21. doi:10.1016/j.pan.2020.10.023
Kras<SUP>P34R</SUP> and Kras<SUP>T58I</SUP> mutations induce distinct RASopathy phenotypes in mice
Wong, J. C., Perez-Mancera, P. A., Huang, T. Q., Kim, J., Grego-Bessa, J., Alzamora, M. D. P., . . . Shannon, K. (2020). Kras<SUP>P34R</SUP> and Kras<SUP>T58I</SUP> mutations induce distinct RASopathy phenotypes in mice. JCI INSIGHT, 5(21). doi:10.1172/jci.insight.140495
Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties.
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F. E., Campbell, F., . . . Costello, E. (2020). Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties.. Cancer Research, 80(13), 2861-2873. doi:10.1158/0008-5472.can-19-3534
A Novel Scaffold-Based Hybrid Multicellular Model for Pancreatic Ductal Adenocarcinoma-Toward a Better Mimicry of the <i>in vivo</i> Tumor Microenvironment
Gupta, P., Perez-Mancera, P. A., Kocher, H., Nisbet, A., Schettino, G., & Velliou, E. G. (2020). A Novel Scaffold-Based Hybrid Multicellular Model for Pancreatic Ductal Adenocarcinoma-Toward a Better Mimicry of the <i>in vivo</i> Tumor Microenvironment. FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 8. doi:10.3389/fbioe.2020.00290
A second site <i>Kras<SUP>G12D</SUP></i> mutation that impairs PI3K binding rescues embryonic lethality, abrogates myeloproliferative disease, and delays lung tumorigenesis.
Wong, J. C., Perez-Mancera, P. A., Kim, J., Jen, K. -Y., Kogan, S. C., Firestone, A. J., . . . Shannon, K. (2020). A second site <i>Kras<SUP>G12D</SUP></i> mutation that impairs PI3K binding rescues embryonic lethality, abrogates myeloproliferative disease, and delays lung tumorigenesis.. In MOLECULAR CANCER RESEARCH Vol. 18 (pp. 43). Retrieved from https://www.webofscience.com/
2019
Chemoradiotherapy screening in a novel biomimetic polymer based pancreatic cancer model
Gupta, P., Totti, S., Perez-Mancera, P. A., Dyke, E., Nisbet, A., Schettino, G., . . . Velliou, E. G. (2019). Chemoradiotherapy screening in a novel biomimetic polymer based pancreatic cancer model. RSC ADVANCES, 9(71), 41649-41663. doi:10.1039/c9ra09123h
Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer
Humpton, T. J., Alagesan, B., DeNicola, G. M., Lu, D., Yordanov, G. N., Leonhardt, C. S., . . . Tuveson, D. A. (2019). Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. CANCER DISCOVERY, 9(9), 1268-1287. doi:10.1158/2159-8290.CD-18-1409
PDAC-associated fibroblasts are less responsive to an anti-fibrotic stimulus and more responsive to a positive regulator of fibroblast activation than normal activated fibroblasts
Barrera, L. N., Evans, A., Lane, B., Brumskill, S., Oldfield, F., Campbell, F., . . . Costello, E. (2019). PDAC-associated fibroblasts are less responsive to an anti-fibrotic stimulus and more responsive to a positive regulator of fibroblast activation than normal activated fibroblasts. Pancreatology, 19, S158. doi:10.1016/j.pan.2019.05.423
Tissue-Specific Oncogenic Activity of KRAS<SUP>A</SUP><SUP>146</SUP><SUP>T</SUP>
Poulin, E. J., Bera, A. K., Lu, J., Lin, Y. -J., Strasser, S. D., Paulo, J. A., . . . Haigis, K. M. (2019). Tissue-Specific Oncogenic Activity of KRAS<SUP>A</SUP><SUP>146</SUP><SUP>T</SUP>. CANCER DISCOVERY, 9(6), 738-755. doi:10.1158/2159-8290.CD-18-1220
2018
A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo
Cassidy, L. D., Young, A. R. J., Perez-Mancera, P. A., Nimmervoll, B., Jaulim, A., Chen, H. -C., . . . Narita, M. (n.d.). A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo. Autophagy, 14(7), 1256-1266. doi:10.1080/15548627.2018.1458172
Disease associated fibroblasts from various pancreatic disorders exhibit subtype specific genetic profile
Barrera, L., Evans, A., Lane, B., Brumskill, S., Oldfield, F., Campbell, F., . . . Costello, E. (2018). Disease associated fibroblasts from various pancreatic disorders exhibit subtype specific genetic profile. Pancreatology, 18(4), S94. doi:10.1016/j.pan.2018.05.254
The efficacy of brusatol as a chemotherapeutic agent in pancreatic cancer and its relevance to potential chemoresistance conferred by Nrf2
Williams, D., Gayon, S., Barrera, L., Perez-Mancera, P., Copple, I., Goldring, C., . . . Costello, E. (2018). The efficacy of brusatol as a chemotherapeutic agent in pancreatic cancer and its relevance to potential chemoresistance conferred by Nrf2. Pancreatology, 18(4), S149. doi:10.1016/j.pan.2018.05.400
Mouse Models of Pancreatic Exocrine Cancer
Pérez-Mancera, P. A. (2018). Mouse Models of Pancreatic Exocrine Cancer. In Pancreatic Cancer (pp. 509-538). Springer New York. doi:10.1007/978-1-4939-7193-0_77
2017
Designing a bio-inspired biomimetic <i>in vitro</i> system for the optimization of <i>ex vivo</i> studies of pancreatic cancer
Totti, S., Vernardis, S. I., Meira, L., Perez-Mancere, P. A., Costello, E., Greenhalf, W., . . . Velliou, E. G. (2017). Designing a bio-inspired biomimetic <i>in vitro</i> system for the optimization of <i>ex vivo</i> studies of pancreatic cancer. DRUG DISCOVERY TODAY, 22(4), 690-701. Retrieved from https://www.webofscience.com/
Generation of Mouse Models of Cancer Using Transposon‐Mediated Approaches
Bermejo‐Rodríguez, C., & Pérez‐Mancera, P. A. (n.d.). Generation of Mouse Models of Cancer Using Transposon‐Mediated Approaches. In Unknown Book (pp. 1-11). Wiley. doi:10.1002/9780470015902.a0026891
Mouse Models of Pancreatic Exocrine Cancer
Pérez-Mancera, P. A. (2017). Mouse Models of Pancreatic Exocrine Cancer. In Pancreatic Cancer (pp. 1-30). Springer New York. doi:10.1007/978-1-4939-6631-8_77-1
2016
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
Ireland, L., Santos, A., Ahmed, M. S., Rainer, C., Nielsen, S. R., Quaranta, V., . . . Mielgo, A. (2016). Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. Cancer Research, 76(23), 6851-6863. doi:10.1158/0008-5472.CAN-16-1201
Identification of novel signalling pathways dysregulated in pancreatic cancer-associated fibroblasts
Barrera, L., Lane, B., Brumskill, S., Oldfield, F., Lamond, R., Wilkinson, L., . . . Costello, E. (2016). Identification of novel signalling pathways dysregulated in pancreatic cancer-associated fibroblasts. Pancreatology, 16(3), S31. doi:10.1016/j.pan.2016.05.106
2015
Use of DNA transposons for functional genetic screens in mouse models of cancer
Bermejo-Rodriguez, C., & Perez-Mancera, P. A. (2015). Use of DNA transposons for functional genetic screens in mouse models of cancer. CURRENT OPINION IN BIOTECHNOLOGY, 35, 103-110. doi:10.1016/j.copbio.2015.05.005
Phenotype Specific Analyses Reveal Distinct Regulatory Mechanism for Chronically Activated p53
Kirschner, K., Samarajiwa, S. A., Cairns, J. M., Menon, S., Perez-Mancera, P. A., Tomimatsu, K., . . . Narita, M. (2015). Phenotype Specific Analyses Reveal Distinct Regulatory Mechanism for Chronically Activated p53. PLOS GENETICS, 11(3). doi:10.1371/journal.pgen.1005053
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Perez-Mancera, P. A., Rashid, M., Iorio, F., . . . Adams, D. J. (2015). BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proceedings of the National Academy of Sciences of the United States of America, 112(6), E536-E545. doi:10.1073/pnas.1418163112
2014
STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma
Evers, L., Perez-Mancera, P. A., Lenkiewicz, E., Tang, N., Aust, D., Knoesel, T., . . . Barrett, M. T. (2014). STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. GENOME MEDICINE, 6. doi:10.1186/gm526
Cancer Cell Signaling
Ayyanathan, K. (Ed.) (n.d.). Cancer Cell Signaling. In . Apple Academic Press. doi:10.1201/b17138
Inside and out: the activities of senescence in cancer
Perez-Mancera, P. A., Young, A. R. J., & Narita, M. (2014). Inside and out: the activities of senescence in cancer. NATURE REVIEWS CANCER, 14(8), 547-558. doi:10.1038/nrc3773